Keywords: cephalon, cep-701, sees, good, ph, ii, data
Cephalon's CEP-701 sees good Ph II data
Article | 09 January 2006
US drugmaker Cephalon says that laboratory findings with patient blood samples demonstrate that its anticancer compound CEP-701 (lestaurtinib) inhibits a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
